CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, TACROLIMUS, YTB323, CYCLOPHOSPHAMIDE, RITUXIMAB, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TOCILIZUMAB, RITUXIMAB
CYTB323L12201
Phase 2 small_molecule active
Quick answer
CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, TACROLIMUS, YTB323, CYCLOPHOSPHAMIDE, RITUXIMAB, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TOCILIZUMAB, RITUXIMAB for Severe refractory idiopathic inflammatory myopathies (IIM) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Severe refractory idiopathic inflammatory myopathies (IIM)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active